title: Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis.
abstract: OBJECTIVE
  To evaluate the intraocular pressure (IOP) outcomes of patients with noninfectious posterior uveitis treated with a fluocinolone acetonide (FA) intravitreal implant over an 8-year period.
  
  
  METHODS
  Retrospective clinical case series.
  
  
  METHODS
  Forty-seven eyes of 35 patients.
  
  
  METHODS
  Retrospective review of medical records of all patients receiving FA implants between June 2001 and March 2009 was performed. Data were pooled to record visual acuity (VA) and to characterize the incidence and outcome of glaucoma surgical intervention.
  
  
  METHODS
  Incidence of glaucoma surgery and IOP before and after glaucoma surgical intervention. Visual acuity before and after FA implant placement.
  
  
  RESULTS
  Nineteen of 42 eyes (45%) receiving FA implants over the course of the study period required glaucoma surgical intervention. Success of IOP-lowering surgery was achieved in 94%, 94%, and 92% of eyes at 6, 12, and 24 months postoperatively. No patient lost more than 1 line of VA. There was an average 2-line gain of acuity at 3 years after FA implant placement for those patients who underwent IOP-lowering surgery.
  
  
  CONCLUSIONS
  Patients receiving FA implants have a significant risk of increased IOP that frequently necessitates glaucoma surgery. Glaucoma surgery, when necessary, offers an effective method to decrease IOP.
  
  
  BACKGROUND
  Proprietary or commercial disclosure may be found after the references.
authors.affiliation: Department of Ophthalmology, Medical College of Georgia, Augusta, Georgia, USA.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Bollinger
authors.forename: James
authors.initials: J
authors.lastname: Kim
authors.forename: Careen Y
authors.initials: CY
authors.lastname: Lowder
authors.forename: Peter K
authors.initials: PK
authors.lastname: Kaiser
authors.forename: Scott D
authors.initials: SD
authors.lastname: Smith
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage; D004343:Drug Implants; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects*; D005901:Glaucoma / Q000139:chemically induced* / Q000601:surgery; D020327:Glaucoma Drainage Implants; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014065:Tonometry, Ocular; D014130:Trabeculectomy; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy*; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D004343:Drug Implants; D005938:Glucocorticoids; D005446:Fluocinolone Acetonide